Spectrum Pharmaceuticals announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS inhibitors in KRASG12C mutant specific cell lines. Jacqulyne Robichaux, Ph.D., Assistant Professor, University of Texas, MD Anderson Cancer Center is presenting a poster titled Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers at the Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10. The conference is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC). The preclinical data demonstrated that inhibition of EGFR, HER2, HER3, and HER4 signaling by the pan-ErbB inhibitor poziotinib was synergistic when combined with KRASG12C inhibitors. These results highlight the importance of HER3 and HER4 signaling, in addition to EGFR and HER2, after KRASG12C inhibition.